Rapid Micro Biosystems Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Rapid Micro Biosystems şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Nov 02

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Oct 29

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Aug 03

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Jun 30

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RPID şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RPID şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Rapid Micro Biosystems Piyasaya Karşı Temettü Getirisi

RPID temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RPID)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Life Sciences)	0.5%
Analist tahmini (RPID) (3 yıla kadar)	n/a

Önemli Temettü: RPID şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RPID şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RPID şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RPID herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Rapid Micro Biosystems Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Rapid Micro Biosystems, Inc. Re-Affirms Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Rapid Micro Biosystems, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Independent Director recently bought US$50k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024

Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.00

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021)

Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook

Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID).

Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million.

Rapid Micro Biosystems, Inc.(NasdaqGS:RPID) dropped from Russell 2500 Value Index

Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance Full Year 2022

Full year 2021 earnings: Revenues in line with analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2021 Results on Mar 04, 2022

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Rapid Micro Biosystems Provides Revenue Guidance for the Full Year 2022

Third quarter 2021 earnings released: US$0.71 loss per share

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year of 2021

Rapid Micro Biosystems, Inc. has completed an IPO in the amount of $158.4 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin